RXRX · Healthcare
RECURSION PHARMACEUTICALS INC
Smart-money confidence
· 1 of 3 sources firing
Weak — few signals
No standout activity across the feeds we track.
Hedge funds
34
Congress
0
Insiders
50
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Limited info. RECURSION PHARMACEUTICALS INC is not currently in our model portfolio, but 6 tracked investors hold it. We're showing what we know from their latest 13F filings.
Market cap
$1.6B
Industry
Biotechnology
Exchange
NasdaqGS
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma;…
6
Investors
3
New positions
2
Increasing
0
Decreasing
1
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.1×
% of portfolio
0.0%
Position change
NEW
0.0% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of D.E. Shaw & Co's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
NEW
0.0% of Millennium Management's portfolio
Trust weight: 1.3×
% of portfolio
1.0%
Position change
+11%
1.0% of ARK Invest's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
+214%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.4×
% of portfolio
0.1%
Position change
—
0.1% of Baillie Gifford & Co's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to RECURSION PHARMACEUTICALS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell RECURSION PHARMACEUTICALS INC or any security.
Get the Weekly Update
Every Sunday, we'll send you what Buffett, Dalio, Ackman and 47 other legendary investors are buying — free, straight from their SEC filings.
Free forever · No spam · Unsubscribe anytime